Table 4.

Outcome of non-motor symptoms and PD-associated symptoms at baseline and after LCIG at each treatment visit

Prospective population without LOCF	Baseline/V1 Mean ± SD	Visit 2 Mean ± SD	Visit 3 Mean ± SD	p vs baseline	p ANOVA for repeated measures
PDQ-39 (score 0–156)	72.3 ± 23.8	64.7 ± 25.4*	67.3 ± 26.4**	*p < 0.001 **p < 0.05	< .0.001
PDSS-2 (score 0–60)	25 ± 10.4	22.5 ± 9.9*	22.7 ± 10.1	*p < 0.01	0.016
GFQ (score 0–64)	29.7 ± 13.3	26.5 ± 13.1*	26.1 ± 12	*p < 0.05	0.079
QUIP-RS (score 0–112)	10.4 ± 16.6	7.8 ± 13*	7.1 ± 10.1*	*p < 0.05	0.011
QUIP-gambling (score 0–16)	1.2 ± 3.3	0.9 ± 2.6	0.5 ± 1.7	NS	0.085
QUIP-sexual behavior	1.5 ± 2.8	1.1 ± 2.5*	1.2 ± 2.7	*p < 0.05	0.140
QUIP-buying	1.5 ± 3.2	1.1 ± 2.3	0.8 ± 1.8	NS	0.100
QUIP-eating	2.2 ± 4	1.8 ± 3.6	1.5 ± 3*	*p < 0.05	0.051
QUIP-hobbism	1.3 ± 2.7	1.2 ± 26	1.3 ± 2.5	NS	0.815
QUIP-punding	1.3 ± 3.4	1 ± 2.6	0.7 ± 1.9	NS	0.128
QUIP-Medication use	1.4 ± 3.5	0.7 ± 2.1*	1.2 ± 3	*p < 0.01	0.093
RSS-2 (score 15–75)	40.2 ± 12.4	39 ± 13.3	38.3 ± 13	NS	0.237
RSS/personal distress	16.5 ± 5.5	16.1 ± 5.7	15.9 ± 5.6	NS	0.467
RSS/negative feeling	9.2 ± 3.6	8.9 ± 3.7	8.7 ± 3.5	NS	0.085
RSS/life upset	14.5 ± 5	14 ± 5.1	13.7 ± 5	NS	0.455

ADL, activities of daily living; BL, baseline; LCIG; levodopa/carbidopa intestinal gel; SD, standard deviation; UPDRS, United Parkinson’s Disease Rating Scale

*p value at V2 vs BL, **p value at V3 vs BL